Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
wilate prophylaxis in young children with severe von Willebrand disease
ISRCTN11217735Phase 3Completed
- Sponsor
- Octapharma
- Start
- Sep 2021
01
Overview
Phase 3, open-label, single-arm trial of von Willebrand factor concentrate in von Willebrand disease (VWD), sponsored by Octapharma. Primary endpoint: Total annualized bleeding rate. Started Sep 2021; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on ISRCTN11217735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11217735.